Über uns

Moderna Therapeutics is developing messenger RNA therapeutics™, a ground-breaking new in vivo drug modality that stimulates production of human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform can be used to address currently undruggable targets and offers improved alternatives to existing drug modalities for a wide range of serious diseases. If successful in human clinical trials, Moderna Therapeutics’ messenger RNA technology will represent the first significant innovation in protein therapeutics since the development of recombinant technology more than 30 years ago, with dramatic implications for both patients and industry. Learn more about the revolutionary science at Moderna Therapeutics.

Moderna Therapeutics is led by a team of seasoned biotechnology executives and scientific and business advisors working to realize the company’s ambitious vision of creating medicines for a broad range of serious diseases associated with high unmet patient needs. Learn more about the leadership at Moderna Therapeutics.

To advance this mission, Moderna Therapeutics has developed a broad intellectual property estate of claims covering novel chemical modifications, RNA engineering, formulation, composition of matter, route of administration, and dosing. The company has established preclinical programs in four key therapeutic areas—oncology supportive care, inherited genetic disorders, hemophilia, and diabetes—and plans to develop and commercialize its innovative messenger RNA therapeutics™, initially for rare diseases and oncology, while partnering drug candidates in other therapeutic areas in order to speed the delivery of this promising technology to patients. The company has a strategic option agreement with AstraZeneca to develop its messenger RNA therapeutics™ to treat cardiovascular, metabolic, and renal diseases, as well as some cancers.

Since its founding, Moderna Therapeutics has published a peer-reviewed manuscript in Nature Biotechnology describing the ability of messenger RNA therapeutics™ to stimulate in vivo production of human proteins and to achieve a long-term therapeutic effect. The study demonstrated that messenger RNA therapeutics™ successfully induced in vivo production of proteins to stimulate blood vessel growth, repair damaged heart tissue, and improve outcomes in a mouse model of myocardial infarction (MI). Moderna Therapeutics has also demonstrated preclinical proof of concept in non-human primates.

Moderna Therapeutics is a privately held company based in Cambridge, Massachusetts, and is well-funded by Flagship Ventures and private investors.

Equipped with novel science, esteemed leadership, and unprecedented funding, the company is expanding rapidly. Learn aboutjob opportunities at Moderna Therapeutics.